John Kanellis

List of Publications by Citations

129 papers	6,132 citations	35 h-index	77 g-index
130 ext. papers	6,939 ext. citations	4.7 avg, IF	5.24 L-index

#	Paper	IF	Citations
129	Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?. *Hypertension*, **2003**, 41, 1183-90	8.5	933
128	Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. *Hypertension*, **2003**, 41, 1287-93	8.5	597
127	Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. *American Journal of Physiology - Renal Physiology*, **2002**, 282, F991-7	4.3	573
126	Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. *Hypertension*, **2002**, 40, 355-60	8.5	413
125	Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. *Seminars in Nephrology*, **2005**, 25, 39-42	4.8	283
124	Role of the microvascular endothelium in progressive renal disease. *Journal of the American Society of Nephrology: JASN*, **2002**, 13, 806-816	12.7	223
123	Decreased allergic lung inflammatory cell egression and increased susceptibility to asphyxiation in MMP2-deficiency. *Nature Immunology*, **2002**, 3, 347-53	19.1	219
122	Hyperuricemia causes glomerular hypertrophy in the rat. *American Journal of Nephrology*, **2003**, 23, 2-7	4.6	198
121	Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. *American Journal of Nephrology*, **2005**, 25, 425-33	4.6	186
120	Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. *Nephrology Dialysis Transplantation*, **2014**, 29, 406-13	4.3	148
119	Effects of Allopurinol on the Progression of Chronic Kidney Disease. *New England Journal of Medicine*, **2020**, 382, 2504-2513	59.2	131
118	Serum uric acid: a risk factor and a target for treatment?. *Journal of the American Society of Nephrology: JASN*, **2006**, 17, S69-73	12.7	113
117	Vascular endothelial growth factor is a survival factor for renal tubular epithelial cells. *American Journal of Physiology - Renal Physiology*, **2000**, 278, F905-15	4.3	98
116	The motivations and experiences of living kidney donors: a thematic synthesis. *American Journal of Kidney Diseases*, **2012**, 60, 15-26	7.4	97
115	A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients. *American Journal of Transplantation*, **2014**, 14, 2106-19	8.7	96
114	Uric acid, endothelial dysfunction and pre-eclampsia: searching for a pathogenetic link. *Journal of Hypertension*, **2004**, 22, 229-35	1.9	71
113	A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection. *Transplantation*, **2009**, 87, 286-9	1.8	60

112	Stanniocalcin-1, an inhibitor of macrophage chemotaxis and chemokinesis. *American Journal of Physiology - Renal Physiology*, **2004**, 286, F356-62	4.3	60
111	Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial. *American Journal of Kidney Diseases*, **2016**, 67, 648-59	7.4	55
110	Increased expression of heparanase in puromycin aminonucleoside nephrosis. *Kidney International*, **2001**, 60, 1287-96	9.9	55
109	Understanding crossmatch testing in organ transplantation: A case-based guide for the general nephrologist. *Nephrology*, **2011**, 16, 125-33	2.2	54
108	Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial. *American Journal of Transplantation*, **2019**, 19, 2876-2888	8.7	51
107	Does asymptomatic hyperuricaemia contribute to the development of renal and cardiovascular disease? An old controversy renewed. *Nephrology*, **2004**, 9, 394-9	2.2	51
106	KHA-CARI guideline: KHA-CARI adaptation of the KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. *Nephrology*, **2012**, 17, 204-14	2.2	47
105	Modulation of inflammation by slit protein in vivo in experimental crescentic glomerulonephritis. *American Journal of Pathology*, **2004**, 165, 341-52	5.8	47
104	Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial. *American Journal of Transplantation*, **2017**, 17, 1853-1867	8.7	46
103	Developing Consensus-Based Priority Outcome Domains for Trials in Kidney Transplantation: A Multinational Delphi Survey With Patients, Caregivers, and Health Professionals. *Transplantation*, **2017**, 101, 1875-1886	1.8	44
102	Redistribution of cytoplasmic VEGF to the basolateral aspect of renal tubular cells in ischemia-reperfusion injury. *Kidney International*, **2000**, 57, 2445-56	9.9	44
101	Challenges of conducting a trial of uric-acid-lowering therapy in CKD. *Nature Reviews Nephrology*, **2011**, 7, 295-300	14.9	40
100	Renal ischemia-reperfusion increases endothelial VEGFR-2 without increasing VEGF or VEGFR-1 expression. *Kidney International*, **2002**, 61, 1696-706	9.9	40
99	Mycophenolate and lower graft function reduce the seroresponse of kidney transplant recipients to pandemic H1N1 vaccination. *Kidney International*, **2012**, 82, 212-9	9.9	39
98	Renal transplant patients at high risk of acute rejection benefit from adequate exposure to mycophenolic acid. *Transplantation*, **2010**, 89, 595-9	1.8	38
97	Diagnostic application of kidney allograft-derived absolute cell-free DNA levels during transplant dysfunction. *American Journal of Transplantation*, **2019**, 19, 1037-1049	8.7	38
96	A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients. *Transplant International*, **2014**, 27, 302-11	3	35
95	The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine. *Kidney International*, **2017**, 91, 954-963	9.9	34

94	JNK signalling in human and experimental renal ischaemia/reperfusion injury. *Nephrology Dialysis Transplantation*, **2010**, 25, 2898-908	4.3	34
93	The CARI guidelines. Justification for living donor kidney transplantation. *Nephrology*, **2010**, 15 Suppl 1, S72-9	2.2	33
92	Inhibition of p38 mitogen-activated protein kinase augments progression of remnant kidney model by activating the ERK pathway. *American Journal of Pathology*, **2004**, 164, 477-85	5.8	31
91	Long-term outcomes of end-stage kidney disease for patients with lupus nephritis. *Kidney International*, **2016**, 89, 1337-45	9.9	29
90	Editorial comment--Elevated uric acid and ischemic stroke: accumulating evidence that it is injurious and not neuroprotective. *Stroke*, **2003**, 34, 1956-7	6.7	27
89	Heparin-binding epidermal growth factor-like growth factor in experimental models of membranous and minimal change nephropathy. *Kidney International*, **1998**, 53, 1162-71	9.9	25
88	Spleen tyrosine kinase promotes acute neutrophil-mediated glomerular injury via activation of JNK and p38 MAPK in rat nephrotoxic serum nephritis. *Laboratory Investigation*, **2011**, 91, 1727-38	5.9	23
87	Macrophages contribute to cellular but not humoral mechanisms of acute rejection in rat renal allografts. *Transplantation*, **2013**, 96, 949-57	1.8	22
86	Slow and steady. Reducing thrombotic events in renal transplant recipients treated with IVIg for antibody-mediated rejection. *Nephrology*, **2011**, 16, 239-42	2.2	22
85	The CARI guidelines. Donor renal function. *Nephrology*, **2010**, 15 Suppl 1, S137-45	2.2	22
84	Heparin-binding epidermal growth factor-like growth factor is expressed in the adhesive lesions of experimental focal glomerular sclerosis. *Kidney International*, **1999**, 55, 2310-21	9.9	22
83	Donor and Recipient Views on Their Relationship in Living Kidney Donation: Thematic Synthesis of Qualitative Studies. *American Journal of Kidney Diseases*, **2017**, 69, 602-616	7.4	21
82	Activators of the energy sensing kinase AMPK inhibit random cell movement and chemotaxis in U937 cells. *Immunology and Cell Biology*, **2006**, 84, 6-12	5	21
81	The Lived Experience of "Being Evaluated" for Organ Donation: Focus Groups with Living Kidney Donors. *Clinical Journal of the American Society of Nephrology: CJASN*, **2017**, 12, 1852-1861	6.9	20
80	A single pathway for the development of essential hypertension. *Cardiology in Review*, **2003**, 11, 180-96	3.2	20
79	Cardiovascular Parameters to 2 years After Kidney Transplantation Following Early Switch to Everolimus Without Calcineurin Inhibitor Therapy: An Analysis of the Randomized ELEVATE Study. *Transplantation*, **2017**, 101, 2612-2620	1.8	18
78	International travel in the immunocompromised patient: a cross-sectional survey of travel advice in 254 consecutive patients. *Internal Medicine Journal*, **2015**, 45, 618-23	1.6	18
77	Early pancreas allograft thrombosis. *Clinical Transplantation*, **2013**, 27, 410-6	3.8	18

76	Establishing a Core Outcome Measure for Life Participation: A Standardized Outcomes in Nephrology-kidney Transplantation Consensus Workshop Report. *Transplantation*, **2019**, 103, 1199-1205	1.8	17
75	Seroresponses and safety of 13-valent pneumococcal conjugate vaccination in kidney transplant recipients. *Transplant Infectious Disease*, **2018**, 20, e12866	2.7	17
74	Identifying Outcomes that Are Important to Living Kidney Donors: A Nominal Group Technique Study. *Clinical Journal of the American Society of Nephrology: CJASN*, **2018**, 13, 916-926	6.9	17
73	Spleen Tyrosine Kinase Signaling Promotes Myeloid Cell Recruitment and Kidney Damage after Renal Ischemia/Reperfusion Injury. *American Journal of Pathology*, **2016**, 186, 2032-2042	5.8	15
72	A study of VEGF and its receptors in two rat models of proteinuria. *Nephron Physiology*, **2004**, 96, P26-36		15
71	Allocation of deceased donor kidneys: A review of international practices. *Nephrology*, **2019**, 24, 591-598	2.2	15
70	Untapped potential in Australian hospitals for organ donation after circulatory death. *Medical Journal of Australia*, **2017**, 207, 294-301	4	14
69	Myeloid cell-mediated renal injury in rapidly progressive glomerulonephritis depends upon spleen tyrosine kinase. *Journal of Pathology*, **2016**, 238, 10-20	9.4	14
68	Suspension and resumption of kidney transplant programmes during the COVID-19 pandemic: perspectives from patients, caregivers and potential living donors - a qualitative study. *Transplant International*, **2020**, 33, 1481-1490	3	13
67	The CARI guidelines. Donors at risk: hypertension. *Nephrology*, **2010**, 15 Suppl 1, S114-20	2.2	13
66	Access to waitlisting for deceased donor kidney transplantation in Australia. *Nephrology*, **2019**, 24, 758-766	2.2	12
65	External validation of the US and UK kidney donor risk indices for deceased donor kidney transplant survival in the Australian and New Zealand population. *Nephrology Dialysis Transplantation*, **2019**, 34, 2127-2131	4.3	11
64	Natural killer cell function predicts severe infection in kidney transplant recipients. *American Journal of Transplantation*, **2019**, 19, 166-177	8.7	11
63	Epstein-Barr virus encephalitis in solid organ transplantation. *New Microbiologica*, **2017**, 40, 212-217	1.1	11
62	Thin basement membrane nephropathy and renal transplantation. *Seminars in Nephrology*, **2005**, 25, 184-7	4.8	10
61	De novo thrombotic microangiopathy following simultaneous pancreas and kidney transplantation managed with eculizumab. *Nephrology*, **2017**, 22 Suppl 1, 23-27	2.2	9
60	Expectations and Experiences of Follow-up and Self-Care After Living Kidney Donation: A Focus Group Study. *Transplantation*, **2017**, 101, 2627-2635	1.8	9
59	Long-term graft survival in patients with chronic antibody-mediated rejection with persistent peritubular capillaritis treated with intravenous immunoglobulin and rituximab. *Clinical Transplantation*, **2017**, 31, e13037	3.8	9

58	Managing psychosis in a renal transplant recipient with bipolar affective disorder and allograft rejection. *Nephrology*, **2015**, 20 Suppl 1, 2-5	2.2	9
57	Cyclophilin Inhibition Protects Against Experimental Acute Kidney Injury and Renal Interstitial Fibrosis. *International Journal of Molecular Sciences*, **2020**, 22,	6.3	9
56	The experiences and impact of being deemed ineligible for living kidney donation: Semi-structured interview study. *Nephrology*, **2020**, 25, 339-350	2.2	9
55	Cyclophilin A Promotes Inflammation in Acute Kidney Injury but Not in Renal Fibrosis. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	8
54	Reducing uric acid as a means to prevent cardiovascular and renal disease. *Expert Opinion on Therapeutic Patents*, **2002**, 12, 193-199	6.8	8
53	Factors associated with anaemia in kidney transplant recipients in the first year after transplantation: a cross-sectional study. *BMC Nephrology*, **2018**, 19, 252	2.7	8
52	De novo or early conversion to everolimus and long-term cancer outcomes in kidney transplant recipients: A trial-based linkage study. *American Journal of Transplantation*, **2018**, 18, 2977-2986	8.7	8
51	Spleen tyrosine kinase contributes to acute renal allograft rejection in the rat. *International Journal of Experimental Pathology*, **2015**, 96, 54-62	2.8	7
50	Confirmed microsporidial graft infection in a HIV-negative renal transplant recipient: A case report and review of the literature. *Transplant Infectious Disease*, **2018**, 20, e12888	2.7	7
49	Skin cancer history, sun-related attitudes, behaviour and sunburn among renal transplant recipients versus general population. *Australasian Journal of Dermatology*, **2018**, 59, e106-e113	1.3	7
48	Inhibition of Spleen Tyrosine Kinase Reduces Renal Allograft Injury in a Rat Model of Acute Antibody-Mediated Rejection in Sensitized Recipients. *Transplantation*, **2017**, 101, e240-e248	1.8	7
47	The CARI guidelines. Donors at risk: proteinuria. *Nephrology*, **2010**, 15 Suppl 1, S106-10	2.2	7
46	Methods in renal research: kidney transplantation in the rat. *Nephrology*, **2016**, 21, 451-6	2.2	6
45	Kidney donation and transplantation in Australia: more than a supply and demand equation. *Medical Journal of Australia*, **2018**, 209, 242-243	4	6
44	Direct and indirect costs incurred by Australian living kidney donors. *Nephrology*, **2018**, 23, 1145-1151	2.2	5
43	Survival and Quality of Life Impact of a Risk-based Allocation Algorithm for Deceased Donor Kidney Transplantation. *Transplantation*, **2018**, 102, 1530-1537	1.8	5
42	Long-term outcomes of end-stage kidney disease for patients with IgA nephropathy: A multi-centre registry study. *Nephrology*, **2016**, 21, 387-96	2.2	5
41	The CARI guidelines. Donors at risk: haematuria. *Nephrology*, **2010**, 15 Suppl 1, S111-3	2.2	5

40	Everolimus and Long-term Clinical Outcomes in Kidney Transplant Recipients: A Registry-based 10-year Follow-up of 5 Randomized Trials. *Transplantation*, **2019**, 103, 1705-1713	1.8	4
39	A simple score can identify kidney transplant recipients at high risk of severe infection over the following 2 years. *Transplant Infectious Disease*, **2019**, 21, e13076	2.7	4
38	Renal transplant ultrasound: The nephrologist's perspective. *Australasian Journal of Ultrasound in Medicine*, **2015**, 18, 134-142	0.6	4
37	Recurrent glomerulopathy in a renal allograft due to lecithin cholesterol acyltransferase deficiency. *Nephrology*, **2016**, 21, 73-4	2.2	4
36	Laboratory identification of donor-derived coxsackievirus b3 transmission. *American Journal of Transplantation*, **2015**, 15, 555-9	8.7	3
35	Initial Australasian experience with portal-enteric drainage in simultaneous pancreas-kidney transplantation. *ANZ Journal of Surgery*, **2010**, 80, 722-7	1	3
34	Initial mycophenolate dose in tacrolimus treated renal transplant recipients, a cohort study comparing leukopaenia, rejection and long-term graft function. *Scientific Reports*, **2020**, 10, 19379	4.9	3
33	Different faces of Nocardia infection in renal transplant recipients. *Nephrology*, **2016**, 21, 254-60	2.2	3
32	Clinicians' attitudes and approaches to evaluating the potential living kidney donor-recipient relationship: An interview study. *Nephrology*, **2019**, 24, 252-262	2.2	3
31	Frequency and outcomes of kidney donation from intensive care patients with acute renal failure requiring renal replacement therapy. *Nephrology*, **2019**, 24, 1296-1303	2.2	2
30	Living donor transplantation: is there inequality of access?. *ANZ Journal of Surgery*, **2011**, 81, 2-3	1	2
29	BK virus RNA can be detected in archival renal transplant biopsies using the reverse trancription polymerase chain reaction. *Nephrology Dialysis Transplantation*, **2009**, 24, 661-6	4.3	2
28	Glomerular lipid deposition: a clue to illicit intravenous drug use. *Nephrology*, **2009**, 14, 358-9	2.2	2
27	Insights into the labeling effect of Kidney Donor Performance Index reporting: The Australian experience. *American Journal of Transplantation*, **2020**, 20, 870-878	8.7	2
26	Kidney transplant recipient perspectives on telehealth during the COVID-19 pandemic. *Transplant International*, **2021**, 34, 1517-1529	3	2
25	Occupational Legionella pneumophila Exposure in a Street Sweeper with a Renal Transplant. *Nephrology*, **2018**, 23, 493-494	2.2	1
24	Transplant Professionals Attitudes and Approaches to the Living Kidney Donor-Recipient Relationship. *Transplantation*, **2017**, 101, S94	1.8	1
23	Transplant considerations in a man with von Hippel-Lindau disease with bilateral renal cell carcinoma and a pancreatic neuroendocrine tumour. *Nephrology*, **2015**, 20, 956-7	2.2	1

22	Implementation and learning of laproscopic donor nephrectomy by a non-transplant general surgeon with advanced laparoscopic skills. *Asian Journal of Endoscopic Surgery*, **2011**, 4, 127-32	1.4	1
21	Cyclophilin D Promotes Acute, but Not Chronic, Kidney Injury in a Mouse Model of Aristolochic Acid Toxicity. *Toxins*, **2021**, 13,	4.9	1
20	Results from an International Survey of Donor and Recipient Eligibility for Solid Organ Pancreas Transplantation. *Annals of Transplantation*, **2021**, 26, e930787	1.4	1
19	Primary central nervous system posttransplant lymphoproliferative disease: An uncommon diagnostic dilemma. *Nephrology*, **2016**, 21, 528	2.2	1
18	Risk Indices in Deceased-donor Organ Allocation for Transplantation: Review From an Australian Perspective. *Transplantation*, **2019**, 103, 875-889	1.8	1
17	KHA-CARI commentary on the KDIGO clinical practice guideline on the evaluation and care of living kidney donors. *Nephrology*, **2020**, 25, 96-98	2.2	1
16	Measurement of Humoral Immune Competence and the Risk of Sinopulmonary Infection in a Cohort of Kidney Transplant Recipients. *Transplantation Proceedings*, **2018**, 50, 3367-3370	1.1	1
15	Factors Associated with Time to Deceased Donor Renal Transplant Waitlisting or Living Donor Transplantation in Australia. *Transplantation*, **2018**, 102, S576	1.8	1
14	A Model of Acute Antibody-Mediated Renal Allograft Rejection in the Sensitized Rata. *Experimental and Clinical Transplantation*, **2018**, 16, 294-300	0.8	0
13	Pregnancy outcomes for simultaneous Pancreas-Kidney transplant recipients versus kidney transplant recipients. *Clinical Transplantation*, **2021**, 35, e14151	3.8	0
12	Jurisdictional inequalities in deceased donor kidney allocation in Australia. *Kidney International*, **2021**, 100, 49-54	9.9	0
11	Recurrent membranoproliferative glomerulonephritis in a renal transplant secondary to monoclonal gammopathy of renal significance successfully treated with bortezomib. *Internal Medicine Journal*, **2019**, 49, 801-802	1.6	
10	The Lived Experience of Being Evaluated For Organ Donation. *Transplantation*, **2017**, 101, S72	1.8	
9	Allocating the unexpected kidney. *Nephrology*, **2012**, 17, 588-9	2.2	
8	Evaluation and Preoperative Management of Kidney Transplant Recipient and Donor **2010**, 1142-1153		
7	Rituximab for Antibody-Mediated Rejection, Less May Be More. *Transplantation*, **2009**, 88, 142-143	1.8	
6	Upregulation of heparin-binding epidermal growth factor-like growth factor and osteopontin in experimental hydronephrosis. *Nephrology*, **2000**, 5, 201-208	2.2	
5	Long-Term Graft and Patient Outcomes Following Kidney Transplantation in End-Stage Kidney Disease Secondary to Hyperoxaluria. *Transplantation Proceedings*, **2021**, 53, 839-847	1.1	

4	Risk indices predicting graft use, graft and patient survival in solid pancreas transplantation: a systematic review. *BMC Gastroenterology*, **2021**, 21, 80	3
3	De Novo or Early Conversion to Everolimus and Cancer Incidence in Kidney Transplant Recipients. *Transplantation*, **2018**, 102, S343	1.8
2	Successful Implementation of an Increased Viral Risk Donor Waiting List for Preconsented Kidney Transplant Candidates in Victoria, Australia. *Transplantation Direct*, **2021**, 7, e758	2.3
1	Donor Predictors of Donor Pancreas Retrieval and Subsequent Solid Pancreas Transplantation in Australia and New Zealand from 2007 to 2016. *Transplantation Proceedings*, **2021**, 53, 2358-2368	1.1